Frontiers in Oncology (Mar 2024)

Prospects and challenges of CAR-T cell therapy combined with ICIs

  • Yufan Lv,
  • Xinyu Luo,
  • Zhuoyi Xie,
  • Jieya Qiu,
  • Jinsai Yang,
  • Yuqi Deng,
  • Rou Long,
  • Guiyang Tang,
  • Chaohui Zhang,
  • Jianhong Zuo,
  • Jianhong Zuo,
  • Jianhong Zuo,
  • Jianhong Zuo

DOI
https://doi.org/10.3389/fonc.2024.1368732
Journal volume & issue
Vol. 14

Abstract

Read online

Immune checkpoint molecules are a group of molecules expressed on the surface of immune cells that primarily regulate their immune homeostasis. Chimeric antigen receptor (CAR) T cell therapy is an immunotherapeutic technology that realizes tumor-targeted killing by constructing synthetic T cells expressing specific antigens through biotechnology. Currently, CAR-T cell therapy has achieved good efficacy in non-solid tumors, but its treatment of solid tumors has not yielded the desired results. Immune checkpoint inhibitors (ICIs) combined with CAR-T cell therapy is a novel combination therapy with high expectations to defeat solid tumors. This review addresses the challenges and expectations of this combination therapy in the treatment of solid tumors.

Keywords